Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Current Deferred Revenue (2016 - 2026)

Intellia Therapeutics has reported Current Deferred Revenue over the past 12 years, most recently at $630000.0 for Q1 2026.

  • Quarterly Current Deferred Revenue fell 98.14% to $630000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $630000.0 through Mar 2026, down 98.14% year-over-year, with the annual reading at $7.3 million for FY2025, 81.27% down from the prior year.
  • Current Deferred Revenue was $630000.0 for Q1 2026 at Intellia Therapeutics, down from $7.3 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $113.2 million in Q1 2022 and troughed at $630000.0 in Q1 2026.
  • The 5-year median for Current Deferred Revenue is $44.8 million (2024), against an average of $46.3 million.
  • Year-over-year, Current Deferred Revenue skyrocketed 71.73% in 2024 and then tumbled 98.14% in 2026.
  • A 5-year view of Current Deferred Revenue shows it stood at $63.8 million in 2022, then dropped by 4.36% to $61.0 million in 2023, then tumbled by 36.19% to $38.9 million in 2024, then tumbled by 81.27% to $7.3 million in 2025, then tumbled by 91.36% to $630000.0 in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Current Deferred Revenue are $630000.0 (Q1 2026), $7.3 million (Q4 2025), and $12.2 million (Q3 2025).